Matt Summerville

Dan gave color (EFD electronics, medical components, interventional recovering) but declined segment-level Q4 outlook.

Naga expects 2027 to build off the peak at mid-single-digit rates; North American chip infrastructure demand still to come.

Dan confirmed medical tracking to 6-8% target, attributed Q2 mix to engineered fluid strength. Interventional headwind from regulatorily required material change, short-term with clear resolution path.

Naga described diversification across dispense and T&I, broader customer base, optimized regional footprint. Called it early stages of cycle with panel-level packaging and optical fibers as emerging opportunities.

CEO described three focus areas: medical components, test and inspection, and core industrial technology additions. Noted multiples elevated in some cases but criteria unchanged, differentiated businesses with strong technology and Nordson-like gross margins.

CFO specified impact was in interventional and Atrion-related fluid components with East Coast operations losing 2-3 days of production, estimating 1% sales impact. Normalized growth would have been approximately 4%.

CEO said M&A strategy unchanged from Investor Day with healthy pipeline but strict strategic and financial discipline, no deals closed in FY2025 because nothing met both criteria. CFO emphasized balanced capital allocation continuing with both buybacks and M&A.

CEO attributed x-ray weakness partly to automotive exposure and partly to a technology transition in inspection, composite chip structures require acoustic for memory and x-ray for logic, with new technologies being tested for FY2027 impact.

CEO estimated 50% of ATS now driven by semiconductor/HPC, up from 20-30% five years ago, with customer base shifting more Asia-centric.

CFO quantified exposure framework: 85-90% in-region, remaining 10-15% diversified with no single intercountry exposure more than low single-digits.

CFO clearly stated year-over-year inflection expected in Q3 to Q4 as destocking comparables ease.

CEO attributed ATS miss to order timing, noting double-digit order entry and backlog growth as encouraging signs.

CFO said current order patterns support guidance, no discernible post-election shift, customers taking wait-and-see approach.

Management declined to give specific segment guidance but implied IPS and MFS roughly flat, with low single-digit ATS growth and Atrion providing overall growth.

Zapico put AI/semis/power/defense/aero at about half of revenue; pure data center is smaller but broadening, and pricing more than offset inflation and tariffs.

CEO quantified record backlog at $4.11B (+21% since year-end) with 1.12 book-to-bill; ~80% ships within 12 months and 2027 is filling in.

Healthcare up low double digits in Q4, up high single digits for full year 2025. Guided mid single digits for 2026 on tougher comps. Healthcare now 21% of AMETEK.

Positive price-cost spread achieved in 2025. Confident pricing will offset inflation and known tariffs in 2026. 30% vitality index, mission-critical products. Price increases are sticky, not temporary offsets.

Paragon had outstanding double-digit++ orders growth, led EMG. Margins in line with AMETEK. Targets 35%+ EBITDA margins when restructuring completes in ~1 year. About halfway through restructuring.

Process improving across all markets and geographies except China. Cost structure well controlled. Management expects excellent Process performance in 2026 when volumes recover.

Automation destocking done. Both Paragon and Automation driving EMG's 260bp core margin expansion. Strong order growth continuing.

Automation expected to lead growth going forward. M&A pipeline strong with $2B capacity, or $4.5-5B at 2.5x leverage. Deployed $1B on two deals acquiring $400M revenue this year.

Orders improved through Q1 with March strongest. April also solid despite tariff concerns. Positive price-cost spread maintained. No clear evidence of prebuying.

Detailed Paragon update: orders up well above 25%, margins at 25%, new management team executing improvement plans. Customers beginning to destock across OEM automation and med tech.

Zapico acknowledged delays were broad-based but emphasized strong orders and improving destocking trends, with some OEM customers through destocking.

Management provided clear pricing vs inflation metrics. Expects inflation to moderate to 1.5-2% range with modest positive price-cost spread.

CEO described HST momentum as generally strong throughout quarter with less nonlinearity. FMT and FSDP showed cadence improvement: soft January, better February, much stronger March, held at that level in April. Bellwether diagnostics overall positive but not uniform. Successful project orders traceable to mega trends like data centers and energy grid.

CEO said core fluidics and optical filters growing low single digits. Pharma remains strong while China market and NIH funding academic pressures continue. Customers guarded on IDEX product inventory positions as expected. Dynamics unchanged from prior quarters. Innovation pipeline gives long-term confidence.

CEO confirmed January also strong. Year-end budget flush not majority of order strength. Momentum building over last 1.5 years with Q4 the strongest mark. Broad-based beyond data centers with good rhythm and cadence. CFO added $20M of temporary cost containment may partially come back in 2026 to fund growth investments.

CEO detailed each sector: energy had positive start but unexpected year-end pause tied to oil prices. European-based chemical franchise pressured. Agriculture in multiyear cycle with orders ebbing around weather. Broad industrial maintaining system-level replacement. Geographic ranking: India best, North America second, Europe third.

Interim CFO confirmed cost containment hedged against volume downturn but current guidance reduction implies slightly more than what it captured. Containment actions are in place and supportive of back half, ramping to full run rate in Q4.

CEO said data center is important for Airtech but not yet a major catalyst for IDEX overall. Interesting initial wins appearing in other places including Muon optical switching. Commercial teams pursuing ability to replicate wins across applications.

CFO clarified $20M absorbs 3-4% volume decline relative to prior outlook, not absolute. CEO added price capture would stand in for some volume loss on top of cost out.

CEO described uniform cadence with slight elevation in HST from Mott/defense/space wins. Customer pre-buy at $6-8M, matching IDEX's own modest level. Not zero but relatively low.

CEO acknowledged the challenging market backdrop is extending assessment timelines but maintained share was held in Q1. Noted strong partner interest in AOS's China business but the weak environment is complicating discussions.

CFO framed this as the logical next step after the retail exit: brand rationalization toward A.O. Smith brand and manufacturing footprint optimization, targeting ~15% operating margins in 2026 and additional 200bp from restructuring in 2027.

Steve noted a few potentially actionable targets in the coming year but maintained discipline. Would not commit to timing or specifics.

Steve did not rule out transformational M&A but noted it takes time. On boilers, expressed caution about back half due to possible prebuy and commercial market uncertainty despite strong H1.

Management acknowledged they are behind the Investor Day growth targets but maintained long-term confidence while admitting dependency on Chinese government stimulus.

Steve clearly outlined channel prioritization: direct-to-consumer, dealer, and wholesale over retail. Still views water treatment as a growth engine with double-digit potential.